NCT01805375 - A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 14, 2017

Study Completion Date

December 14, 2017

Conditions

Indolent B-cell LymphomaChronic Lymphocytic LeukaemiaWaldenström Macroglobulinaemia

Interventions

DRUG

DI-B4

DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.

Trial Locations (5)

L7 8XP

Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool

M20 4BX

The Christie NHS Foundation Trust, Manchester

OX3 7LE

The Churchill Hospital, Oxford

PL6 8DH

Derriford Hospital, Plymouth

S016 6YD

University Hospital Southampton NHS Foundation Trust, Southampton